Private Label Surrogacy
Menu
Choosing an agency

What are surrogacy success rates, and how should they be defined?

The short answer

A surrogacy success rate is only meaningful when you know the denominator. There are three different numbers: live birth rate per embryo transfer (clinical, reported by SART for gestational carrier cycles, and driven mainly by embryo quality and the intended mother's or donor's age); live birth rate per journey (the share of matched intended parents who bring a baby home, which includes rematches and repeated transfers); and match rate (the share of signed parents who are matched), which says nothing about births. Ask an agency which it is quoting. Private Label Surrogacy reports journeys and births since 2017 as more than 100 and more than 60, and does not publish a blended percentage.

Portrait of Mark Silverberg, DDS, MD, of Private Label Surrogacy

Written by Mark Silverberg, DDS, MD

Reviews the surrogate's available medical records before she is presented to intended parents.

Medically reviewed by Mark Silverberg, DDS, MD, October 2026

Last updated

Two fathers on a sofa holding their sleeping baby between them

Why are there three different 'success rates'?

Because each one divides a different number by a different number. A success rate is a fraction. Until you know the numerator and the denominator, a percentage tells you nothing.

The three you will see quoted:

  1. Live birth rate per embryo transfer. Of all embryo transfers into a gestational carrier, how many led to a live birth? This is a clinical measure. It is reported by fertility clinics to SART and the CDC, and it depends mostly on the embryo.
  2. Live birth rate per journey. Of all intended parents who matched with a surrogate, how many brought a baby home, however many transfers or rematches it took? This is the number most parents care about. It depends on the embryos, the surrogate, and whether the journey holds together through setbacks.
  3. Match rate. Of all intended parents who signed with an agency, how many were matched with a surrogate? This is an agency process measure. It says nothing about pregnancies or births.

All three are legitimate. They answer different questions. The problem comes when one is quoted as if it were another, or when they are blended into a single figure with no definition.

Metric Numerator Denominator Who reports it What it tells you What it hides
Live birth rate per transfer Live births Embryo transfers into a gestational carrier Clinics, to SART and the CDC How likely one transfer is to succeed How many transfers a family needed; embryo selection differences between clinics
Live birth rate per journey Families who brought a baby home Families who matched Agencies, if they choose to How likely a matched family is to finish with a baby How long it took; how many families left before matching
Match rate Families matched Families who signed Agencies How reliably an agency finds surrogates Whether any of those matches led to a birth
Blended "success rate" Undefined Undefined Marketing Nothing you can check Everything above

What does SART report for gestational carrier cycles?

SART, the Society for Assisted Reproductive Technology, collects outcome data from its member clinics and publishes it, including cycles that use a gestational carrier. The CDC publishes national assisted reproductive technology data from clinic reports as well.

These reports are useful for one thing: understanding how often an embryo transfer into a gestational carrier results in a live birth, broken down by factors such as the age of the person whose eggs were used. They are reported per transfer or per cycle, not per surrogacy journey.

Many transfers do not result in a pregnancy, and your clinic can tell you its own rate. After several unsuccessful transfers, the clinic reviews the plan with you before the next one.

Two cautions when you read clinic data. First, clinics differ in which patients they treat and how they select embryos, so clinic-to-clinic comparisons need care. Second, a per-transfer number is not your chance of bringing a baby home. Many families need more than one transfer.

What drives per-transfer success: embryo quality, PGT-A, carrier screening

Three factors carry most of the weight in whether a single transfer succeeds.

Embryo quality. This is the largest single factor. Embryo quality is driven mainly by the age of the person whose eggs created the embryo at the time the eggs were retrieved. Embryos from younger eggs, including donor eggs, are more likely to be chromosomally normal. See embryo quality.

PGT-A. Preimplantation genetic testing for aneuploidy checks embryos for an abnormal number of chromosomes before transfer. Selecting a chromosomally normal (euploid) embryo raises the chance that a given transfer succeeds and lowers the chance of miscarriage from chromosomal causes. It does not create more viable embryos. Whether to test embryos is a decision between you and your doctor, and clinics name the testing differently; ASRM does not recommend it routinely for every patient (Practice Committee, 2024). If you have three embryos and one is euploid, PGT-A tells you which one to transfer first; it does not change how many you have. See PGT testing.

Carrier screening. A gestational carrier has already shown she can carry a healthy full-term pregnancy. Careful screening of her medical history makes it more likely her uterus and her health support implantation and a healthy pregnancy. At Private Label Surrogacy, Mark Silverberg, DDS, MD, reviews the surrogate's available medical records, summarizes them and flags inconsistencies before she is presented to you. All available records go to your fertility clinic. His summary is confidential: only PLS and your clinic receive it. The clinic then does its own medical screening. A pregnancy is not guaranteed by either step. Both reduce avoidable risk.

The clinic's lab, the transfer technique and the medication protocol matter too. Those are your clinic's responsibility, and SART data by clinic is one way to look at them.

What drives per-journey success: rematch, repeated transfers, persistence

A journey succeeds when a family brings a baby home. Getting there often takes more than one transfer, and sometimes more than one surrogate.

Repeated transfers. If the first transfer does not lead to a pregnancy, a second transfer with another embryo is common. The pregnancy test comes 9 to 11 days after each transfer. Each additional transfer adds a medical cycle, which the clinic usually plans within a few months after further tests, plus travel, monitoring and clinic fees, and the surrogate's transfer fee. See failed transfers and miscarriage.

Embryo supply. A family with several euploid embryos can try again without a new IVF cycle. A family with one embryo left may need to create more before the next transfer.

Keeping the match together. After a failed transfer, a surrogate and intended parents have to decide together whether to try again. That depends on trust, clear communication and support for the surrogate. A match that breaks down after a failed transfer adds months.

Rematch. Sometimes a surrogate cannot continue, for medical or personal reasons. A rematch with a new screened surrogate keeps the journey going. The Platinum Plan ($62,500*) includes unlimited rematches and no second agency fee if the first surrogate cannot proceed (she withdraws, does not pass clinic screening, or the match ends before a live birth). Clinic and surrogate costs still apply, so it is not a fixed price. The Platinum Plan does not limit surrogate compensation.

The agency's influence on per-journey success is indirect: the quality of surrogate screening, how well it coordinates with your clinic, and whether it keeps the match intact through a setback. That is where an agency earns its fee. It cannot change your embryos.

Why a match rate is not a success rate

A match rate measures how often an agency finds a surrogate for families who sign. It is an operations number. It can be very high at an agency whose matches often fail, if it matches quickly with candidates who have not been fully screened and later fail clinic clearance.

A high match rate is good to have. It is not evidence about births. If an agency quotes a high percentage, ask: "Is that the share of families matched, or the share who brought a baby home?"

How to read an agency's claimed rate

When an agency quotes a single high percentage, ask four questions:

  1. What is the numerator? Pregnancies, live births, or matches?
  2. What is the denominator? Transfers, matched families, or signed families? Are families who left the program counted?
  3. Over what period? Since founding, last year, or a selected window?
  4. Who calculated it? The agency itself, or a clinic reporting to SART?

A claim that cannot answer all four is not a statistic. It is a slogan. Claims of near-perfect success deserve particular care.

A made-up example shows how much the denominator matters. Suppose an agency signs 100 families in a year. Ninety are matched. Of those 90, 70 bring a baby home within two years; some of the rest are still trying, and some stopped. The same agency could truthfully say "90% match rate," "78% of matched families had a baby," or "70% of families who signed had a baby." It could also quote a per-transfer rate from its partner clinics that is different again. Each number is accurate. Only one of them answers your question.

Also ask what happens to families for whom the journey did not succeed. An agency that can describe how it handled failed transfers and rematches is telling you more than one that only quotes a rate.

What PLS publishes and why

Private Label Surrogacy does not publish a blended percentage. We are building a yearly report on journeys started, matches completed and births, each with its definition. Clinical outcomes are decided by independent physicians and clinics, so we report them only where we can track them reliably.

We do not publish a single success percentage because it would blend clinical factors we do not control (your embryos, your clinic's lab) with agency factors we do (surrogate screening, coordination, keeping the match together). A blended figure would hide the one thing you need to know: which of the two is driving your own odds.

What we can tell you is what we do on the agency side. A doctor reviews the surrogate's available medical records. Every surrogate completes an independent psychological evaluation before her profile is shown. Nancy is involved in every match and oversees it. Your case manager manages the day-to-day journey. And when a transfer fails, the people who help you decide what comes next have been through it.

For your clinical odds, ask your fertility clinic about your embryos. For the agency side, judge us on the criteria for choosing an agency.

Sources

  • SART, Society for Assisted Reproductive Technology, national summary and clinic data on gestational carrier cycles.
  • CDC, Assisted Reproductive Technology (ART) surveillance data.
  • ASRM, American Society for Reproductive Medicine, guidance on preimplantation genetic testing and gestational carriers.
Questions people ask

Frequently asked questions

What is the success rate of surrogacy?

Per transfer, live birth rates for gestational carrier cycles are reported by SART; many transfers do not result in a pregnancy, and your clinic can tell you its own rate; per journey, the result depends on the embryos, the surrogate and whether the journey holds together through setbacks, and often more than one transfer is needed.

Why does PLS not publish a percentage?

Because a single percentage blends clinical and agency factors; PLS publishes journeys and births since 2017 and defines each.

Does the agency affect success?

Indirectly: through surrogate screening quality, clinic coordination, and keeping a match intact through a failed transfer.

Does PGT-A raise the success rate?

It raises the per-transfer rate by selecting chromosomally normal embryos; it does not create more viable embryos. Whether to test embryos is a decision between you and your doctor, and clinics name the testing differently; ASRM does not recommend it routinely for every patient (Practice Committee, 2024).

* Excludes third-party fees, including but not limited to medical fees.

Read next